Breast Cancer
Featured Article
“The data obtained in our study quantify the economic value of delaying or preventing disease progression and may inform payers and physician groups about value-based payment programs,” researchers wrote.
In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implications of HER2+ breast cancer treatment in the era of biosimilars…
Adam Brufsky, MD, PhD, and Sreejata Raychaudhuri, MD, recently discussed how the novel HER2+ therapies fit into breast cancer treatment.